# HIV context
## Notes on drugs availability
Merck (that has raltegravir, the first INI drug on the market) also had a fixed-dose pill raltegravir+lamivudine (Dutrebis). It was approved by the FDA in 2015, yet Merck decided not to make the drug commercially available due to business reasons (ostensibly because the drugs were available as separate agents, and due to upcoming full-combo fixed-dose pills). IN 2017 Merck has asked to withdraw EMA authorisation
